Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Fig. 3

Survival analysis of OS in BM patients. a The patients that developed initial BM after first-generation EGFR-TKIs had inferior OS than those that developed initial BM after osimertinib resistance had occurred; b The patients receiving RT had a significantly longer OS than those without RT; c In the multivariate model, sex, and brain RT were independently associated with OS in the BM patient group

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us